12:00 AM
 | 
Jun 03, 2013
 |  BC Week In Review  |  Company News  |  Deals

BeiGene, Merck KGaA deal

BeiGene granted Merck exclusive, ex-Chinese rights to develop and commercialize BeiGene-283, a small molecule BRAF inhibitor in preclinical development for cancer....

Read the full 104 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >